PostNovember 10, 2026
Marvel says MB-204 normalised autism-linked behaviours in Shank3 mice that its parent Parkinson's drug did not
Marvel Biosciences says MB-204 returned six behaviours to normal in a Shank3 mouse model of autism, as it readies a first Phase 1 trial in Australia.
B
BiotechNews.io4 min read
